P. Bizouard

发表

CYP 2D6 PM phenotype hypothesis of antidepressant extrapyramidal side-effects.

P. Vandel, D. Sechter, B. Bonin, 1996, Medical hypotheses.

Carbamazepine, fluvoxamine. Is there a pharmacokinetic interaction?

D. Sechter, S. Vandel, S. Nezelof, 1992, Therapie.

PHARMACOKINETICS OF FLUOXETINE AND FLUVOXAMINE IN DEPRESSED PATIENTS: PERSONAL RESULTS

G. Bertschy, D. Sechter, B. Bonin, 1992, Clinical neuropharmacology.

Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes

J. Daléry, E. Haffen, P. Vandel, 1999, European Journal of Clinical Pharmacology.

The thyrotropin-releasing hormone test: some statistical considerations

C. A. de Mendonça Lima, S. Vandel, P. Bizouard, 1992, European psychiatry.

[Are anxiety or depressive disorders more frequent among one of the anorexia or bulimia nervosa subtype?].

O. Halfon, M. Flament, N. Godart, 2005, L'Encephale.

Mood disorders in eating disorder patients: Prevalence and chronology of ONSET.

O. Halfon, M. Flament, N. Godart, 2015, Journal of affective disorders.

Tricyclic antidepressant-induced extrapyramidal side effects.

P. Vandel, D. Sechter, B. Bonin, 1997, European Neuropsychopharmacology.

[Abuse of tianeptine. A case report].

P. Vandel, D. Sechter, B. Bonin, 1999, L'Encephale.

Psychoactive substance consumption in eating disorders.

O. Guilbaud, M. Speranza, O. Halfon, 2001, Eating behaviors.

[Amineptin dependence. Detection of patients at risk. Report of 8 cases].

G. Bertschy, S. Vandel, P. Bizouard, 1990, L'Encephale.

Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients.

G. Bertschy, D. Sechter, P. Baumann, 1995, Pharmacological research.

Tricyclic antidepressant plasma levels after fluoxetine addition.

B Vandel, G. Bertschy, D. Sechter, 1992, Neuropsychobiology.

Paroxetine and Galactorrhea

P. Vandel, D. Sechter, B. Bonin, 1997, Pharmacopsychiatry.

[Prediction of suicide risk].

G. Bertschy, D. Sechter, B. Bonin, 1991, L'Encephale.

Factorial structure of the 20-item Toronto Alexithymia Scale: confirmatory factorial analyses in nonclinical and clinical samples.

J. Guelfi, P. Stéphan, F. Pérez-Diaz, 2001, Journal of psychosomatic research.

[Thyroid function in depressed patients].

C. A. de Mendonça Lima, G. Bertschy, B. Bonin, 1996, L'Encephale.

Predictive factors of social disability in anorexic and bulimic patients

O. Halfon, N. Godart, M. Corcos, 2004, Eating and weight disorders : EWD.

[Yawning and sexual excitation under clomipramine. Role of serotoninergic mechanisms. Apropos of 2 cases].

G. Bertschy, D. Sechter, S. Vandel, 1991, L'Encephale.

[Pertinence of the addiction concept in eating behavior disorders].

O. Halfon, M. Flament, M. Corcos, 2000, Annales de medecine interne.

Influence of CYP2D6*2 and CYP2D6*4 alleles on phenotype in polymedicated depressed inpatients: therapeutic consequences?

E. Haffen, P. Bechtel, P. Vandel, 2000, European Journal of Clinical Pharmacology.

[Consumption of benzodiazepines in a university hospital center].

G. Bertschy, B. Bonin, S. Vandel, 1992, L'Encephale.

Does the frequency of anxiety and depressive disorders differ between diagnostic subtypes of anorexia nervosa and bulimia?

Martine Flament, Olivier Halfon, Sylvie Berthoz, 2006, The International journal of eating disorders.

Citalopram: an Interaction Study with Clomipramine in a Patient Heterozygous for CYP2D6 Genotype

P. Bechtel, P. Vandel, D. Sechter, 1999, Pharmacopsychiatry.

METABOLIC INTERACTION BETWEEN TRICYCLIC ANTIDEPRESSANT AND FLUVOXAMINE AND FLUOXETINE, A PHARMACOGENETIC APPROACH

G. Bertschy, D. Sechter, P. Baumann, 1992, Clinical neuropharmacology.